Loading...
Loading...
PCRX| Name | Value |
|---|---|
| Revenues | 172.0M |
| Cost of Revenue | 61.9M |
| Gross Profit | 110.0M |
| Operating Expense | 95.8M |
| Operating I/L | 17.1M |
| Other Income/Expense | -35.2M |
| Interest Income | 2.8M |
| Pretax | -18.1M |
| Income Tax Expense | -8.0M |
| Net Income/Loss | -10.1M |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions in the United States. The company's flagship products include EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used for targeted nerve treatment. Additionally, Pacira BioSciences develops proprietary multivesicular liposome drug delivery technology, encapsulating drugs without altering their molecular structure.
